Survival_determinants_in_extensive-stage_non-small-cell_lung_cancer:_the_Southwest_Oncology_Group_experience._We_analyzed_the_2,531-patient_Southwest_Oncology_Group_extensive-stage_non-small-cell_lung_cancer_(ENSCLC)_data_base_from_1974_to_1988_to_(1)_assess_the_interactions_of_host-_or_tumor-related_prognostic_factors_and_therapy_using_Cox_modeling_and_recursive_partitioning_and_amalgamation_(RPA)_to_determine_whether_each_independently_predicts_outcome,_and_(2)_use_RPA_to_define_prognostic_subsets_with_different_survival_potentials._Good_performance_status_(PS),_female_sex,_and_age_greater_than_or_equal_to_70_years_were_significant_independent_predictors_in_a_Cox_model_applied_to_the_entire_population._In_a_second_Cox_model_for_patients_with_good_PS_enrolled_on_recent_studies,_hemoglobin_level_greater_than_or_equal_to_11.0_g/dL,_normal_lactate_dehydrogenase_(LDH),_normal_calcium,_and_a_single_metastatic_site_were_significant_favorable_factors._The_use_of_cisplatin_was_an_additional_independent_predictor_of_improved_outcome_in_both_Cox_models_after_adjustments_for_year_of_accrual_and_all_prognostic_variables._The_favorable_effect_of_cisplatin_was_observed_in_each_of_six_RPA-derived_subgroups_from_the_entire_population._A_second_RPA_of_904_patients_from_recent_trials_(nearly_all_received_cisplatin-based_therapy)_resulted_in_three_distinct_prognostic_subsets_based_on_PS,_age,_hemoglobin,_and_LDH;_greater_than_or_equal_to_1-year_survivals_were_27%,_16%,_and_6%_(P_less_than_.0001)._The_best_survival_occurred_for_patients_with_a_good_PS_who_had_a_hemoglobin_level_greater_than_or_equal_to_11_g/dL_and_who_were_older_than_47_years._This_analysis_suggests_that_although_several_factors_were_independent_variables_in_the_Cox_models,_three_important_prognostic_subgroups_were_easily_defined_through_RPA._Together_with_other_analyses,_our_results_suggest_the_need_to_modify_the_stage_IV_category_in_NSCLC.